> top > docs > PubMed:26984210 > annotations

PubMed:26984210 JSONTXT

Annnotations TAB JSON ListView MergeView

wangzhuo19_800_2

Id Subject Object Predicate Lexical cue
T1 43-54 CI denotes PF-06439535
T2 178-189 CI denotes PF-06439535
T3 502-513 CI denotes PF-06439535
T4 1137-1148 CI denotes PF-06439535
T5 1357-1368 CI denotes PF-06439535
T6 1611-1622 CI denotes PF-06439535
T7 1760-1771 CI denotes PF-06439535
T8 85-96 CI denotes bevacizumab
T9 203-214 CI denotes bevacizumab
T10 230-241 CI denotes bevacizumab
T11 275-286 CI denotes bevacizumab
T12 300-311 CI denotes bevacizumab
T13 324-335 CI denotes bevacizumab
T14 342-353 CI denotes bevacizumab
T15 515-526 CI denotes bevacizumab
T16 534-545 CI denotes bevacizumab
T17 1152-1163 CI denotes bevacizumab
T18 1170-1181 CI denotes bevacizumab
T19 1193-1204 CI denotes bevacizumab
T20 1211-1222 CI denotes bevacizumab
T21 1370-1381 CI denotes bevacizumab
T22 1390-1401 CI denotes bevacizumab
T23 1624-1635 CI denotes bevacizumab
T24 1644-1655 CI denotes bevacizumab
T25 1780-1791 CI denotes bevacizumab
T26 1799-1810 CI denotes bevacizumab
T27 1822-1833 CI denotes bevacizumab
T28 1840-1851 CI denotes bevacizumab

yangbin123xm_800_3

Id Subject Object Predicate Lexical cue
T1 85-96 CI denotes bevacizumab
T2 203-214 CI denotes bevacizumab
T22 43-54 CI denotes PF-06439535
T23 178-189 CI denotes PF-06439535
T24 502-513 CI denotes PF-06439535
T25 1137-1148 CI denotes PF-06439535
T26 1357-1368 CI denotes PF-06439535
T27 1611-1622 CI denotes PF-06439535
T28 1760-1771 CI denotes PF-06439535
T3 230-241 CI denotes bevacizumab
T29 324-338 CI denotes bevacizumab-EU
T30 275-289 CI denotes bevacizumab-EU
T31 515-529 CI denotes bevacizumab-EU
T32 1152-1166 CI denotes bevacizumab-EU
T33 1193-1207 CI denotes bevacizumab-EU
T34 1370-1384 CI denotes bevacizumab-EU
T35 1624-1638 CI denotes bevacizumab-EU
T36 1780-1794 CI denotes bevacizumab-EU
T37 1822-1836 CI denotes bevacizumab-EU
T38 342-356 CI denotes bevacizumab-US
T39 300-314 CI denotes bevacizumab-US
T40 534-548 CI denotes bevacizumab-US
T41 1170-1184 CI denotes bevacizumab-US
T42 1211-1225 CI denotes bevacizumab-US
T43 1390-1404 CI denotes bevacizumab-US
T44 1644-1658 CI denotes bevacizumab-US
T45 1799-1813 CI denotes bevacizumab-US
T46 1840-1854 CI denotes bevacizumab-US

chenxin_473849_800_3

Id Subject Object Predicate Lexical cue
T1 43-54 CI denotes PF-06439535
T10 515-529 CI denotes bevacizumab-EU
T11 1152-1166 CI denotes bevacizumab-EU
T12 1193-1207 CI denotes bevacizumab-EU
T13 1370-1384 CI denotes bevacizumab-EU
T14 1624-1638 CI denotes bevacizumab-EU
T15 1780-1794 CI denotes bevacizumab-EU
T16 1822-1836 CI denotes bevacizumab-EU
T17 300-314 CI denotes bevacizumab-US
T18 342-356 CI denotes bevacizumab-US
T19 534-548 CI denotes bevacizumab-US
T2 178-189 CI denotes PF-06439535
T20 1170-1184 CI denotes bevacizumab-US
T21 1211-1225 CI denotes bevacizumab-US
T22 1390-1404 CI denotes bevacizumab-US
T23 1644-1658 CI denotes bevacizumab-US
T24 1799-1813 CI denotes bevacizumab-US
T25 1840-1854 CI denotes bevacizumab-US
T26 203-214 CI denotes bevacizumab
T27 85-96 CI denotes bevacizumab
T3 502-513 CI denotes PF-06439535
T4 1137-1148 CI denotes PF-06439535
T5 1357-1368 CI denotes PF-06439535
T6 1611-1622 CI denotes PF-06439535
T7 1760-1771 CI denotes PF-06439535
T8 275-289 CI denotes bevacizumab-EU
T9 324-338 CI denotes bevacizumab-EU
T28 230-241 CI denotes bevacizumab